Key result
Plasma miR-1 levels above 1.22 demonstrated high diagnostic potential for acute heart failure with a sensitivity of 77.2%, specificity of 97.7%, and an AUC of 0.841.
Why the study?
Circulating miRNAs show promise in cardiovascular diseases, but their diagnostic and prognostic value in acute heart failure needed evaluation.
Do plasma levels of miR-1, -21, -23, and -423-5-p have diagnostic and prognostic value in patients with acute heart failure?
Case-Control (n=88)
No
Do plasma levels of miR-1, -21, -23, and -423-5-p have diagnostic and prognostic value in patients with acute heart failure?
Effect estimate: AUC 0.841 (95% CI 0.751-0.946)
p-value: p=0.001
Plasma levels of miR-1, -21, -23, and -423-5-p show high diagnostic accuracy for acute heart failure but do not predict one-year clinical outcomes.
May support miR-1 testing in acute heart failure diagnosis; hypothesis-generating and requires prospective validation.
BACKGROUND: A number of circulating micro-ribonucleic acids (miRNAs) have been introduced as convincing predictive determinants in a variety of cardiovascular diseases. This study aimed to evaluate some miRNAs' diagnostic and prognostic value in patients with acute heart failure (AHF). METHOD: Forty-four AHF patients were randomly selected from a tertiary heart center, and 44 healthy participants were included in the control group. Plasma levels of assessed miRNAs, including miR -1, -21, -23, and -423-5-p were measured in both groups. The patients were followed for one year, and several clinical outcomes, including in-hospital mortality, one-year mortality, and the number of readmissions, were recorded. RESULTS: An overall 88 plasma samples were evaluated. There was no significant difference in terms of demographic characteristics between the AHF and healthy groups. Our findings revealed that mean levels of miR-1, -21, -23, and -423-5-p in AHF patients were significantly higher than in the control group. Although all assessed miRNAs demonstrated high diagnostic potential, the highest sensitivity (77.2%) and specificity (97.7%) is related to miR-1 for the values above 1.22 (p = 0.001, AUC = 0.841; 95%CI, 0.751 to 946). Besides, the levels of miR-21 and -23 were significantly lower in patients with ischemia-induced HF. However, the follow-up data demonstrated no significant association between miRNAs and prognostic outcomes including in-hospital mortality, one-year mortality, and the number of readmissions. CONCLUSION: The result of our study demonstrated that miR-1, -21, -23, and -423-5-p can be taken into account as diagnostic aids for AHF. Nevertheless, there was no evidence supporting the efficacy of these miRNAs as prognostic factors in our study.
No takes yet. Share an insight, caveat, or question.
Sadat‐Ebrahimi et al. (2022) conducted a case-control in Acute heart failure (n=88). Plasma miR-1 level vs. Healthy controls was evaluated on Diagnosis of acute heart failure (AUC 0.841, 95% CI 0.751-0.946, p=0.001). Plasma miR-1 levels above 1.22 demonstrated high diagnostic potential for acute heart failure with a sensitivity of 77.2%, specificity of 97.7%, and an AUC of 0.841.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: